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Abstract
Background: Microglia are resident macrophages of the central nervous system (CNS) locally maintained through
colony-stimulating factor 1 receptor (CSF1R) signaling. Microglial depletion via CSF1R inactivation improves
cognition in mouse models of neuroinflammation, but limits virologic control in the CNS of mouse models of
neurotropic infections by unknown mechanisms. We hypothesize that CSF1R plays a critical role in myeloid cell
responses that restrict viral replication and locally restimulate recruited antiviral T cells within the CNS.
Methods: The impact of CSF1R signaling during West Nile virus infection was assessed in vivo using a mouse
model of neurotropic infection. Pharmacological inactivation of CSF1R was achieved using PLX5622 prior to
infection with virulent or attenuated strains of West Nile virus (WNV), an emerging neuropathogen. The subsequent
effect of CSF1R antagonism on virologic control was assessed by measuring mortality and viral titers in the CNS and
peripheral organs. Immune responses were assessed by flow cytometric-based phenotypic analyses of both
peripheral and CNS immune cells.
Results: Mice treated with CSF1R antagonist prior to infection exhibited higher susceptibility to lethal WNV
infection and lack of virologic control in both the CNS and periphery. CSFR1 antagonism reduced B7 co-stimulatory
signals on peripheral and CNS antigen-presenting cells (APCs) by depleting CNS cellular sources, which limited local
reactivation of CNS-infiltrating virus-specific T cells and reduced viral clearance.
Conclusions: Our results demonstrate the impact of CSF1R antagonism on APC activation in the CNS and
periphery and the importance of microglia in orchestrating the CNS immune response following neurotropic viral
infection. These data will be an important consideration when assessing the benefit of CSF1R antagonism, which
has been investigated as a therapeutic for neurodegenerative conditions, in which neuroinflammation is a
contributing factor.
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Background
West Nile virus (WNV) is an emerging human pathogen
that causes seasonal outbreaks through the Western
hemisphere since its introduction in 1999 [1]. A member
of the Flavivirus genus, WNV is an enveloped,
single-stranded positive sense RNA virus that cycles
between birds and mosquitos. Symptoms of WNV
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infection can range from a relatively mild flu-like illness,
West Nile fever, to severe neuroinvasive disease. After
peripheral infection, WNV replicates within lymphoid
tissues before entering the CNS, where it targets neurons in the cerebellum, brainstem, and cerebral cortex
[2, 3]. In 2017, 2002 symptomatic WNV cases were reported to the CDC, and of those, 1339 (67%) were classified as neuroinvasive [4]. Prolonged neurological deficits,
which include motor functions, verbal learning and
memory, and executive functions, are a significant problem for survivors of WNV infection and appear to manifest even in cases where neuroinvasion is absent [5–7].
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Recent work indicates that persistent phagocytic microglia contribute to prolonged cognitive dysfunction following WNV encephalitis [8], and thus, limiting
microglial activation may alleviate the associated neurological sequelae.
Microglia are the resident immune cells in the CNS,
originating from yolk sac progenitor cells that seed the
brain early in development [9]. In addition to a multitude of homeostatic functions throughout development
and healthy aging [10, 11], microglia participate in both
innate and adaptive immune responses through recognition of pathogen-associated molecular patterns and
damage-associated molecular patterns [12], which stimulate morphological changes [13, 14] and increase production of reactive oxidative species [15, 16] and
cytokines/chemokines [17, 18]. During neurotropic virus
infection, virally infected cells secrete chemokines
including CCL2, CCL5, and CXCL10, which facilitate
immune cells crossing the blood brain barrier (BBB)
[19–21]. Mononuclear cell infiltration into the CNS is a
hallmark of WNV encephalitis, and monocytes and T
cells are critical for CNS virologic control. Elimination
of monocytes using a liposome-encapsulated drug
dichloromethylene diphosphonate or by genetic deletion
of CCR2 increases mortality in mice infected with a
neurotropic strain of WNV [22, 23]. However, monocytes may also contribute to dissemination of virus to
the CNS [24, 25], and inhibition of monocyte infiltration
may also protect against nitric oxide-mediated immunopathology [26]. CD4+ T cells produce antiviral molecules, such as interferon γ (IFNγ) and IL-2, which
promotes antiviral humoral immunity and sustains
WNV-specific CD8+ T cell responses, enabling viral
clearance in all organs [27, 28]. CD8+ T cells contribute
to viral clearance and recovery from WNV infection via
both cytopathic and noncytopathic mechanisms [29–32].
Mice lacking either CD8+ T cells or MHC-I molecules
have higher CNS viral burdens, increased mortality after
infection, and prolonged viral persistence, suggesting
that cell-mediated immunity controls virus within the
CNS [32].
CSF1 receptor (CSF1R) signaling is essential for the
development of many mononuclear phagocytes including microglia. Tissue-resident macrophages, such as
microglia, fail to develop in Csf1r−/− mice [9], but in
contrast to many tissue macrophages, adult microglia
can still form in Csf1op/op mice, which carry a natural
null mutation in the Csf1 gene [33]. This is due to an alternative CSF1R ligand, IL-34, which is highly expressed
by neurons [34, 35]. Similar to Csf1op/op mice, IL-34−/−
mice develop fewer microglia but do not lack peripheral
macrophages [36]. These mice are more susceptible to
lethal neurotropic WNV infection, which is associated
with increased neuronal apoptosis without increased
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viral replication [36]. In order to temporally control
microglial depletion, pharmacologic agents that
antagonize CSF1R have been developed, including antagonist PLX5622, which depletes microglia in as little as
3 days and may be sustained for at least 6 weeks [37].
These agents are being investigated as therapeutics in
models of neurodegenerative diseases in which microglial activation is considered a contributing factor, such
as traumatic brain injury [38, 39], experimental autoimmune encephalomyelitis [40], and Alzheimer’s disease
[41]. Here, we used PLX5622 in a model of WNV encephalitis to examine the effect of CSF1R antagonism in
the setting of neurotropic viral infection. Our results
show that mice treated with PLX5622 are more susceptible to lethal WNV infection, which is associated with increased CNS viral burden and neuronal apoptosis.
PLX5622 also reduced expression of proinflammatory cytokines and B7 co-stimulatory molecules within the infected CNS by depleting cellular sources, including
resident microglia and infiltrating macrophages, as well as
decreasing expression on peripheral antigen-presenting
cells (APCs). The loss of APCs in the CNS resulted in limited local reactivation of recruited antiviral CD8+ T cells,
which are required for virologic control in the CNS. Together, these data demonstrate the impact of CSF1R antagonism on APC activation during viral infection in both
the CNS and periphery and highlight the importance of
microglia in orchestrating cell-mediated antiviral immunity during neurotropic infection.

Methods
Ethics statement

All experiments were performed in strict compliance
with the recommendations in the Guide for the Care
and Use of Laboratory Animals of the National Institutes
of Health and according to the international Guiding
Principles for Biomedical Research Involving Animals.
The protocol was approved by the Washington
University School of Medicine in St Louis Animal Safety
Committee (#20170064).
Viruses

WNV-NY is strain 3000.0259, isolated in New York in
2000 [42] and passaged twice in C6/36 Aedes albopictus
cells to generate an insect cell-derived stock for f.p. inoculations. For i.c. inoculations of WNV-NY, virus strain
3000.0259 was passaged once in Vero cells to generate
mammalian cell-derived stock. Attenuated WNV-NS5E218A was constructed from WNV 3356 strain as described previously [43, 44] and was passaged once in
Vero cells, as described previously [45]. Stock titers for
all viruses were determined using BHK21 cells for viral
plaque assay as previously described [46].
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Mouse experiments

Table 1 Primer and probe sequences used for qRT-PCR

All mice used in these experiments were male C57BL/6
inbred mice obtained commercially (The Jackson
Laboratory). All mice were housed in pathogen-free
facilities at the Washington University School of Medicine. PLX5622 was provided by Plexxikon Inc. and formulated in AIN-76A rodent diet at a dose of 1200 mg/kg by
Research Diets. Mice were provided PLX5622 or control
AIN-76A chow starting at 6 weeks of age for 2 weeks. For
viral inoculations, mice were anesthesthetized with a cocktail of ketamine/xylazine/acepromazine, then inoculated
subcutaneously via footpad injection (f.p., 50 μl) or intracranially (i.c., 10 μl) with a guided 29G needle into the
brain’s third ventricle.

Target

Viral tissue burden and viremia quantification

For in vivo virus replication experiments, mice were infected with WNV and euthanized at specific days
post-infection, as indicated. For tissue collection, mice were
deeply anesthetized with ketamine/xylazine/acepromazine,
blood collected in serum separator tubes, then transcardially perfused with sterile Dulbecco’s phosphate-buffered
saline (dPBS; Gibco). The spleen and kidneys were collected, then the brain and spinal cord removed and microdissected. All organs were snap frozen, weighed, and then
homogenized in dPBS. Virus was titered by standard
plaque assay with BHK21 cells, as described previously
[46]. Serum viremia was measured using TaqMan quantitative RT-PCR (qRT-PCR) primers and probe listed in
Table 1, as described previously [47].

Primer sequence (5′➔3′)

GAPDH
Fwd

GGC AAA TTC AAC GGC ACA GT

Rev

AGA TGG TGA TGG GCT TCC C

IFNα
Fwd

CTT CCA CAG GAT CAC TGT GTA CCT

Rev

TTC TGC TCT GAC CAC CTC CC

IFNβ
Fwd

CTG GAG CAG CTG AAT GGA AAG

Rev

CTT CTC CGT CAT CTC CAT AGG G

IFNγ
Fwd

AAC GCT ACA CAC TGC ATC TTG G

Rev

GCC GTG GCA GTA ACA GCC

TNFα
Fwd

GCA CAG AAA GCA TGA TCC G

Rev

GCC CCC CAT CTT TTG GG

iNOS
Fwd

GGA GCC TTT AGA CCT CAA CAG A

Rev

TGA ACG AGG AGG GTG GTG

CD86
Fwd

ACG ATG GAC CCC AGA TGC ACC A

Rev

GCG TCT CCA CGG AAA CAG CA

CD68
Fwd

CCA CAG GCA GCA CAG TGG ACA

Rev

TCC ACA GCA GAA GCT TTG GCC C

Arg1

Leukocyte isolation and flow cytometry

For flow cytometry experiments, mice were deeply anesthetized with ketamine/xylazine/acepromazine, then
blood was collected in 5 μM EDTA in dPBS (Gibco).
Mice were transcardially perfused with dPBS, and then,
the spleen, brain, popliteal LNs, and femur were removed. Bone marrow was collected from the femur by
centrifuging the bone in a 0.65-ml microtube punctured
with an 18G needle nested inside a 1.7-ml tube. Brain
tissue was minced and digested in a HBSS (Gibco) containing 0.05% collagenase D (Sigma), 0.1 μg/ml TLCK
trypsin inhibitor (Sigma), 10 μg/ml DNase I (Sigma), and
10 mM Hepes pH 7.4 (Gibco) for 1 h at 22 °C with shaking. Brain, spleen, and LN tissues were pushed
through a 70-μm strainer and centrifuged at 500g for
10 min. Brain cell pellets were resuspended in 37%
isotonic Percoll (GE healthcare) and centrifuged at
1200g for 30 min to remove myelin debris, and pellet
was resuspended in dPBS. Red blood cells were lysed
in blood, spleen, and bone marrow samples with ACK
lysing buffer (Gibco) for 5 min, then centrifuged at
500g for 10 min and resuspended in dPBS. Prior to
immunostaining, all cells were blocked with 1:50

Fwd

TTA GGC CAA GGT GCT TGC TGC C

Rev

TAC CAT GGC CCT GAG GAG GTT C

TGFβ
Fwd

TAC TAT GCT AAA GAG GTC ACC C

Rev

CTT CCC GAA TGT CTG ACG TAT TG

IL10
Fwd

TTG GAA TTC CCT GGG TGA GAA

Rev

GGA GAA ATC GAT GAC AGC GC

WNV
Fwd

TCA GCG ATC TCT CCA CCA AAG

Rev

GGG TCA GCA CGT TTG TCA TTG

Probe /56-FAM/TGC CCG ACC /ZEN/ ATG GGA GAA GCT C/3IABkFQ/

TruStain FcX anti-mouse CD16/32 (Clone 93, Biolegend, Cat 101320) for 5 min. Cells were stained with
antibodies, as indicated for 15 min at 22 °C, then
washed thrice with dPBS, and fixed with 2% paraformaldehyde (PFA). Data were collected with a BD LSR
Fortessa X-20 flow cytometer and analyzed with
FlowJo software.
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Flow cytometry antibodies

All used at 1:200: CD11b (Clone M1/70, Biolegend, Cat
10137), CD45 (Clone 30-F11, eBioscience, Cat
56-0451-82), MHCII (Clone M5/114.15.2, Biolegend, Cat
107626), CD86 (Clone GL1, BD Biosciences, 553691),
CD80 (Clone 16-10A1, Biolegend, 104706), CD11c
(Clone N418, Biolegend, Cat 117335), CD103 (Clone
2E7, eBioscience, Cat 48-1031-80), CD8a (Clone 53-6.7,
Biolegend, Cat 100712), CD4 (Clone RM4-5, BD Biosciences, Cat 550954), CD69 (Clone H1.2F3, eBiosciene,
Cat 12-0691-81), Ly6C (Clone HK1.4, Biolegend, Cat
128003), Ly6G (Clone 1A8, Biolegend, Cat 127616),
CD160 (Clone 7H1, Biolegend, Cat 143007),
Rat-anti-P2RY12 (Clone S16007D, Biolegend, Cat
848002), and Goat-anti-Rat-AlexaFluor 350 (Invitrogen,
Cat A21093). WNV-specific CD8+ T cells were identified with fluorescent-labeled immunodominant Db-restricted NS4B peptide.
Quantitative RT-PCR

RNA was isolated from tissue homogenates using Qiagen RNeasy kit according to the manufacturer’s instructions. RNA was treated with DNAse, then cDNA was
synthesized using random primers and MultiScribe reverse transcriptase (Applied Biosystems). A single
reverse-transcriptase master mix was used to
reverse-transcribe all samples in order to minimize differences in reverse-transcription efficiency using the following conditions: 25 °C for 10 min, 48 °C for 30 min,
and 95 °C for 5 min. For all primers except WNV,
qRT-PCR was performed using Power SYBR Green PCR
mastermix, and data are reported as ΔCt (Cttarget −
CtGAPDH). Viral RNA was isolated from serum using
Qiagen Viral RNA kit. A standard curve of viral genome
with known PFU and serum samples were quantified
using TaqMan reagents and the primers and probe listed
in Table 1.
Tunel stain, immunohistochemistry, and confocal microscopy

Following perfusion with ice cold PBS and 4% paraformaldehyde (PFA), brains were immersion-fixed overnight in 4% PFA, followed by cryoprotection in two
exchanges of 30% sucrose for 48 h, then frozen in OCT
(Fisher). Ten-micrometer sagittal sections were cut, then
washed with PBS, and permeabilized with 0.1% Triton
X-100/0.1% sodium citrate. Tunel reaction was prepared
according to the manufacturer’s directions (Roche in situ
cell death kit, TMR Red, Cat 12-156-792-910). Sections
were immunostained for NeuN or Iba1 by blocking sections with 5% goat serum/0.1% Tween 20/PBS, then incubating overnight at 4 °C with rabbit-anti-NeuN (1:1000,
Clone D3S3I, Cell Signaling Technology Cat 12943S) or
rabbit-anti-Iba1 (1:1000, Wako Cat 019-19741). Sections
were washed with 0.1% Tween 20/PBS, then incubated
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with goat-anti-rabbit-AF488 (4 μg/ml, Invitrogen, Cat
A11008), counterstained with 1 μg/ml DAPI, and coverslipped with Prolong Gold Antifade Mountant (ThermoFisher, Cat P36930). Z-stack images (seven images
separated by 1 μm) were captured using a Zeiss LSM 510
laser-scanning confocal microscope at × 40 objective magnification then compressed into a maximum intensity projection with accompanying software. For each region of
each mouse, three to six images were taken from two
different sagittal sections spaced at least 50 μm apart.
The number of DAPI-positive nuclei also positive for
NeuN and Tunel were counted by an individual
blinded to the conditions.
Statistical analysis

Statistical analyses were performed using Prism 7.0
(GraphPad Software). All data were analyzed using an unpaired t test or two-way ANOVA with Sidak’s post-test to
correct for multiple comparisons, as indicated in the corresponding figure legends. A P value < 0.05 was considered significant.

Results
CSF1R antagonism depletes myeloid populations within
peripheral blood and CNS

CSF1R signaling is essential for the development of
mononuclear phagocytes including microglia, but
pharmacological antagonism has been reported to selectively deplete microglia [48]. To examine the impact of
CSF1R antagonism on both peripheral and CNS mononuclear cells, we used PLX5622, which reportedly depletes microglia in as little as 3 days and may be
sustained for at least 6 weeks [37, 41]. Mice were provided either control chow or PLX5622-embedded chow
for 2 weeks, after which microglia numbers were
assessed by flow cytometry using the microglia-specific
marker P2RY12 (Additional file 1) and by immunohistochemistry using Iba1 (Additional file 2). Quantification
shows that 2 weeks of PLX5622 treatment reduced
microglia in the CNS by 90–95% (Additional file 1 A–F,
P, Q). Specificity of P2RY12 for CNS-resident microglia
is demonstrated by lack of staining in leukocytes isolated
from peripheral immune compartments (Additional file 1
G–O). Within the CNS, PLX5622 treatment significantly
depleted microglia across hippocampal, cortical, and
cerebellar brain regions (Additional file 2). To determine
whether PLX5622 treatment depleted mononuclear cells
in peripheral immune compartments, we assessed numbers of antigen-presenting cells (APCs, Fig. 1) and T
cells (Additional file 3) in the spleen and blood of uninfected mice in control versus PLX5622-treated mice.
PLX5622 treatment significantly reduced circulating
CD11c+ (Fig. 1a–c), MHCII+CD11c+ (Fig. 1d–f ), and
CD11bnegCD11c+ (Fig. 1g–i) cells in the blood. In the
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(See figure on previous page.)
Fig. 1 CSF1R antagonism reduces circulating APC populations in uninfected mice. Mice were fed PLX5622 chow or control chow for 2 weeks, and
APCs were assessed in blood (a–i) and spleen (j–r). a, j Representative flow cytometry plots of CD11c expression on CD45+ cells. b, k Quantification of
percentages and c, l total numbers of CD45+CD11c+ cells. d, m Representative flow cytometry plots of MHCII expression on CD11c+CD45+. e, n
Quantification of percentages and f, o total numbers of MHCII+CD11c+CD45+ cells. g, p Representative flow cytometry plots of CD103 vs CD11b
expression on CD11c+CD45+ cells. h, q Quantification of percentages and i, r total numbers of (I) CD103+CD11bnegCD11c+CD45+, (II)
CD103+CD11b+CD11c+CD45+, (III) CD103negCD11b+CD11c+CD45+, and (IV) CD103negCD11bnegCD11c+CD45+ cells. For quantification panels, each
symbol represents an individual control (black) or PLX5622-treated (red) mouse, and bars indicate mean ± SEM. Data shown represent analysis from
one experiment with three to five mice per group, repeated in three independent experiments. Statistical significance was calculated using two-way
ANOVA with Sidak’s multiple comparisons test. For all data: ns, not significant at P < 0.05; *P < 0.05; **P < 0.01; ***P < 0.001. CTRL: Control; PLX: PLX5622

spleen, however, there was no significant difference in
populations of APCs with PLX5622 treatment (Fig. 1j–r).
In addition, no significant difference in populations of T
cells was detected in uninfected mice in either compartment (Additional file 3). Because of the sensitivity of
microglia and APCs to CSF1R antagonism, we assessed
whether CSF1R antagonism depleted CD11b+, Ly6C+, and
Ly6G+ cells in the blood, spleen, and bone marrow of
PLX5622-treated versus control-treated uninfected mice.
Flow cytometry analysis revealed no significant differences
in populations of these cells in uninfected mice
(Additional file 4). Together, these data indicate that
circulating APCs, but not bone marrow or splenic
mononuclear cells, are decreased in the context of
CSF1R antagonism.
CSF1R antagonism increases susceptibility of mice to fatal
WNV infection

To determine whether CSF1R antagonism impacts survival from WNV infection, mice were fed
PLX5622-embedded chow for 2 weeks, then infected
with WNV-NY [42] at either 102 or 104 PFU via footpad
(f.p.) inoculation. Consistent with published data [8, 49],
30% of control-treated mice survived infection with 104
PFU and 90% of control-treated mice survived infection
with 102 PFU; however, mice treated with PLX5622 universally succumbed to infection with either inoculum
titer (Fig. 2a). This was associated with significantly increased weight loss (Fig. 2b) and more severe clinical
score (Fig. 2c, d) in PLX5622-treated compared with
control-treated mice infected with 102 PFU WNV-NY.
To determine whether increased mortality caused by
PLX5622 treatment is associated with increased viral
replication in peripheral or CNS tissues, tissue viral
loads were assessed by plaque assay, and serum viral
loads were determined by quantitative RT-PCR
(qRT-PCR) at 2, 4, 6, and 8 days post-infection (dpi). In
the CNS, virus was first detected in the olfactory bulb
(Fig. 2e), then sequentially in more caudal regions including the cortex (Fig. 2f ), cerebellum (Fig. 2g), brainstem (Fig. 2h), and spinal cord (Fig. 2i). Compared with
control-treated animals, PLX5622-treated mice exhibited
higher viral titers in the olfactory bulb and cortex at 6
and 8 dpi and in the cerebellum, brainstem, and spinal

cord at 8 dpi; however, viral titers were also significantly
higher in peripheral tissues of PLX5622-treated mice including the spleen at 4 dpi (Fig. 2j), kidney at 4 and
6 dpi (Fig. 2k), and serum at 2, 4, 6, and 8 dpi (Fig. 2l).
PLX5622 treatment did not cause increased BBB permeability in infected mice (Additional file 5). Once
WNV-NY enters the CNS via intracranial (i.c.) inoculation,
PLX5622 treatment did not affect neuronal permissivity to
infection (Additional file 6). Together, these data indicate a
loss of immune-mediated virologic control in both peripheral and CNS tissues in CSF1R antagonist-treated mice,
consistent with prior data suggesting that CSF1R signaling
plays important roles in the function of both peripheral
and CNS myeloid cells [50–52].
To determine whether microglia depletion impacts innate immune mechanisms of virologic control specifically within the CNS, mice were fed control or
PLX5622-embedded chow for 2 weeks, then i.c. infected
with an attenuated strain of WNV (WNV-NS5-E218A)
at 104 PFU. The NS5-E218A point mutation abolishes
2′-O-methyltransferase activity, which functions to
methylate the 5′ cap of viral RNA and facilitate escape
of IFN-induced proteins with tetratricopeptide repeats
(IFIT)-mediated suppression; thus, this attenuation
limits viral replication by increasing sensitivity of the
virus to type I IFN-mediated innate immune mechanisms [45, 49]. Despite this attenuation, mice treated
with PLX5622 were significantly more susceptible to lethal WNV-NS5-E218A infection than those receiving
control chow (Fig. 3a). Weight loss was also significantly
increased in PLX5622-treated mice (Fig. 3b). Consistent
with this, viral titers measured by plaque assay at 2, 4, 6,
and 8 dpi in the olfactory bulb (Fig. 3d), cortex (Fig. 3e),
cerebellum (Fig. 3f ), brainstem (Fig. 3g), and spinal cord
(Fig. 3h) were significantly higher in PLX5622-treated
compared in control-treated mice infected with
WNV-NS5-E218A. As virus was inoculated into the cortex, it was detected there at 2 dpi, followed by spread to
the olfactory bulb by 4 dpi, and cerebellum, brainstem,
and spinal cord by 6 dpi. PLX5622 treatment also led to
decreased proinflammatory cytokine expression in the
cortex at 8 dpi (Fig. 3c) and increased neuronal apoptosis in the hippocampus and cerebellum at 6 dpi
(Fig. 3l–p) after i.c. infection with WNV-NS5-E218A.
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Fig. 2 PLX5622-treated mice exhibit increased mortality, increased encephalitis score, and impaired virologic control compared with control mice
following peripheral infection with WNV-NY. a–d Mice were fed chow containing PLX5622 or control chow for 2 weeks, then infected with 102 or
104 PFU via footpad infection, then monitored for (a) mortality, (b) weight loss, and (c, d) encephalitis score for up to 25 dpi. a Survival curves
show a significant increase in mortality in mice treated with PLX5622 compared with control-treated mice infected with either viral inoculum
dose, as calculated by log-rank (Mantel-Cox) test. b Weight was measured daily during acute illness as a measure of illness. After death, the last
measured weight was carried through to the end of the experiment. Significantly greater weight loss was measured in PLX5622-treated mice
compared with controls infected with 102 PFU as calculated by two-way ANOVA with matched values comparing group means without multiple
comparisons. c Clinical scores of PLX5622 or control-treated mice infected with 102 PFU or d 104 PFU as indicated during acute illness.
0 = subclinical, 1 = hunched/ruffled fur, 2 = altered gate/slow movement, 3 = no movement, but responsive to stimuli, 4 = moribund, 5 = dead.
e–k Tissue viral loads as measured by plaque assay at 2, 4, 6, and 8 dpi following infection with 102 PFU in control (black) or PLX5622-treated
(red) mice. l Serum viral loads as measured by qRT-PCR. e–l Data are presented as scatter plots with each mouse represented by a dot with the
SEM indicated by a line. Dotted lines in e–l indicate assay limit of detection. All data presented are the compilation of two independent
experiments with 10 mice per group. Statistical significance was calculated using two-way ANOVA with Sidak’s multiple comparisons test. For all
data: ns, not significant at P < 0.05; *P < 0.05; **P < 0.01; ****P < 0.0001

As expected, WNV-NS5-E218A was barely detected in
the kidney (Fig. 3j), and the virus was steadily cleared
from the serum (Fig. 3k) in both control- and
PLX5622-treated mice. However, significantly higher
levels of virus were detected in the spleen of PLX5622versus control-treated, WNV-NS5-E218A-infected mice

at 4 dpi (Fig. 3i), which was consistent with data obtained during f.p. infection with WNV-NY. Overall,
CSF1R antagonism leads to enhanced mortality and loss
of virologic control in both the periphery and CNS regardless of the WNV strain utilized, suggesting a critical
role for this molecule in antiviral immunity.
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(See figure on previous page.)
Fig. 3 CSF1R antagonism increases mortality and CNS viral burdens during i.c. infection with WNV-NS5-E218A. Mice were fed chow containing
PLX5622 or control chow for 2 weeks, infected i.c. with WNV-NS5-E218A at 104 PFU, then monitored for a mortality and b weight loss for up to
25 dpi. a Survival curves show a significant increase in mortality in mice treated with PLX5622 compared with control as calculated by log-rank
(Mantel-Cox) test. b Weight was measured daily during acute illness as a measure of illness. After death, the last measured weight was carried
through to the end of the experiment. Significantly greater weight loss was measured in PLX5622-treated mice compared with controls as
calculated by two-way ANOVA with matched values comparing group means without multiple comparisons. For a and b, data represent the
compilation of two independent experiments with 10 mice per group. c At 8 dpi, cortical brain tissue was extracted and relative transcript levels
in tissue homogenates were measured by SYBR qRT-PCR for indicated cytokines. Data for individual mice were normalized to Gapdh. Data are
presented as mean ± SEM of three to five mice from one experiment. Statistical significance between treatment groups for each cytokine was
calculated by t test. d–j Tissue viral loads were measured by plaque assay at 2, 4, 6, and 8 dpi in control (black) or PLX5622-treated (red) mice.
k Serum viral loads as measured by qRT-PCR. d–k Data are presented as scatter plots with each mouse represented by a dot with the mean
indicated by a line. For d–k, data represent the compilation of two-independent experiments with 10 mice per group. Dotted lines in
d–k indicate assay limit of detection. l–o Representative confocal microscopic images of Tunel (red), NeuN (green), and DAPI (blue) of
hippocampus (l, m) and cerebellum (n, o) of control- (l, n) or PLX5622-treated (m, o) mice infected i.c. with WNV-NS5-E218A at 6 dpi. Arrow
heads point to DAPI-positive nuclei positive for both Tunel and NeuN. Asterisks denote DAPI- and Tunel-positive but NeuN-negative nuclei.
p Quantification of confocal microscopic images for number of DAPI-positive nuclei positive for Tunel and NeuN in the hippocampus (Hpc),
cerebellum (Cb), and brainstem (Bs). The number of Tunel+ NeuN+ nuclei per high-power field (HPF) was quantified from three to six images
captured at × 40 per brain region across two separate brain sections for each of five independent mice collected in one experiment. Each symbol
represents the average number for an individual mouse, with bar indicating mean ± SEM. Statistical significance was calculated using two-way
ANOVA with Sidak’s multiple comparisons test. For all data: ns, not significant at P < 0.05; *P < 0.05; **P < 0.01; ****P < 0.0001

CSF1R signaling is required for activation of APC
co-stimulatory function

To determine whether alterations in APC populations
impact antiviral immune responses, control- and PLX5622#treated mice were infected via f.p. with WNV-NY (100
PFU). After f.p. infection, WNV-infected cells traffic to
draining popliteal lymph nodes (pLN) and stimulate an
antiviral immune response [53]. At 4 dpi, a time-point of
high serum viral loads (Fig. 2l), flow cytometric assessment
revealed a trend towards decreased CD11c+CD45+ cells in
the blood (Fig. 4a–d) and significantly reduced percentages
and total numbers of CD11c+CD45+ cells in the pLN of
PLX5622-treated compared with control-treated mice
(Fig. 4k–n). There was no difference in numbers or percentages of MHCII+CD11c+CD45+ cells in either blood or
pLN (Fig. 4e–g, o–q); however, the percentages of
CD11c+CD45+ cells in the blood positive for co-stimulatory
molecule CD80+ was significantly decreased in PLX5622versus control-treated mice (Fig. 4h–j). In the pLN, the
numbers and percentages of CD11c+CD45+ cells positive
for co-stimulatory molecule CD86 were significantly reduced in PLX5622-treated mice compared with control
mice (Fig. 4r–t). The impact of CSF1R antagonism on
CD80 and CD86 expression appears to be tissuedependent as the blood showed no difference in APCs
expressing CD86 and the pLN showed no difference in
APCs expressing CD80 (Additional file 7). Together,
these data indicate that CSF1R antagonism decreases
the expression of co-stimulatory B7 molecules on peripheral APC populations.
Because infectious virus was detected in the spleens of
mice infected i.c. with WNV-NS5-E218A (Fig. 3i),
splenic APCs were analyzed using flow cytometry at
8 dpi. Results indicated no significant difference in the

numbers or percentages of MHCII+CD11c+CD45+ cells
in the spleens of PLX5622-treated mice compared with
control-treated mice (Fig. 5a–c). However, splenic APCs
collected from PLX5622-treated mice exhibited significantly reduced populations of cells expressing
co-stimulatory molecules CD80 (Fig. 5d–f) and CD86
(Fig. 5g–i) compared with control-treated mice. Furthermore, splenic MHCII+CD11c+CD45+ cells showed significant reduction in the expression level of CD86 (Fig. 5l, m)
and non-significant reduction of CD80 (Fig. 5j, k) in
PLX5622-treated compared with control-treated mice.
This correlated with a small, but significant increase in
the numbers of CD4+ and CD8+ T cells, but no difference
in numbers or percentages of WNV-specific NS4B
tetramer staining or CD69 positivity in spleens of
PLX5622-treated mice compared with control-treated
mice infected i.c. with WNV-NS5-E218A (Additional file 8). Together, these data indicate that
CSF1R antagonism reduces the activation of inflammatory responses in peripheral APCs even without
significant depletion.
Loss of cellular sources of co-stimulatory signals in the
CNS results in decreased T cell reactivation

Microglia are hypothesized to act as immediate responders to CNS pathogens as resident APCs that coordinate intra-parenchymal adaptive immune response
[54]. Previous studies indicated that clearance of WNV
in the CNS requires antiviral CD8+ T cells [19, 32, 55],
and that microglia, astrocytes, and neurons express
chemokines that attract mononuclear cells to the CNS
[21, 56, 57]. To determine the impact of CSF1R antagonism on recruitment of these cells to the CNS, leukocytes
isolated from the cortices of WNV-NS5-E218A-infected
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Fig. 4 CSF1R antagonism reduces response of APCs in peripheral immune compartments following peripheral infection with WNV-NY. Mice were
fed PLX5622 or control chow for 2 weeks, then infected via f.p. with WNV-NY (100 PFU). At 4 dpi, leukocytes were isolated from blood (a–j) and
draining popliteal LNs (k–t). a, k Representative flow cytometry plots of CD11c expression on CD45+-gated cells and b, l fluorescence minus one
(FMO) gating controls. c, m Quantification of percentages and d, n total numbers of CD11c+ CD45+ cells. e, o Representative flow cytometry
plots of MHCII+ expression on CD11c+CD45+ cells. f, p Quantification of percentages and g, q total numbers of MHCII+CD11c+CD45+ cells.
h Representative flow cytometry plots of CD86+ expression on CD11c+CD45+ cells. i Quantification of percentages and j total numbers of
CD86+CD11c+CD45+ cells. r Representative flow cytometry plots of CD80+ expression on CD11c+CD45+ cells. s Quantification of percentages and
t total numbers of CD80+CD11c+CD45+ cells. For quantification panels, each symbol represents an individual control- (black) or PLX5622-treated
(red) mouse, and bars indicate mean ± SEM. Data shown represent analysis from one experiment with three to five mice per group. Statistical
significance was calculated using unpaired t test in all panels except d and n, which used two-way ANOVA with Sidak’s multiple comparisons
test. For all data: ns, not significant at P < 0.05; *P < 0.05; **P < 0.01

mice were assessed by flow cytometry at 8 dpi. As expected, CD45loCD11b+ (P1) population, which is primarily
microglia [58], remained significantly depleted in the
PLX5622-treated compared with control-treated mice
(Fig. 6a–c). The population of CD45hiCD11b+ (P2), which
is primarily infiltrating monocytes/macrophages [58], were
non-significantly reduced in the PLX5622-treated compared with control-treated mice. However, the number of
CD45hiCD11bneg (P3) lymphocyte population [58] were
non-significantly elevated in PLX5622-treated compared
with control mice, though the percentage of this population was significantly elevated (Fig. 6a–c). This increase
was largely due to elevated numbers of CD8+ T cell infiltration in PLX5622-treated mice (Fig. 6d–f). Though
there was no significant difference in the percentage of
CD8+ T cells specific for the WNV immunodominant
peptide between PLX5622 and control-treated mice, there
were significantly more WNV-specific CD8+ T cells isolated from PLX5622 compared with control-treated cortex
(Fig. 6g–i). Despite the increased infiltration of
WNV-specific CD8+ T cells in PLX5622-treated mice, the
percentages of cells expressing early activation marker
CD69 and their level of expression were significantly reduced in PLX5622-treated compared with control-treated
mice (Fig. 6j–m). Additionally, the percentage of
WNV-specific CD8+ T cells positive for CD160 as well as
the level of CD160 expression, which is specifically
expressed on highly activated CD8+ T cells [59], were reduced in PLX5622-treated compared with control-treated
mice. However, the numbers of NS4B+CD8+ cells positive
for either CD69 or CD160 were non-significantly elevated
in PLX5622-treated compared with control-treated cortices (Fig. 6l, p) due to the increased numbers of NS4B
+CD8+ cells.
Because numbers of infiltrating WNV-specific CD8+ T
cells derived from the CNS of PLX5622-treated animals
were increased, we hypothesized that their lack of local
reactivation may be the result of loss of co-stimulatory
signals and/or inflammatory cytokines (Fig. 3c) in the
CNS. In order to distinguish resident microglia from infiltrating monocytes/macrophages, CNS myeloid cells
were examined for expression of the microglia-specific

marker P2RY12 (Fig. 7a). Infiltrating monocytes/
macrophages were then identified via gating of
P2RY12negCD11b+ cells (Fig. 7b). Populations of both
CNS-derived P2RY12+CD45+ microglia (P1, Fig. 7a) and
CD11b+P2RY12negCD45+ monocytes/macrophages (P2,
Fig. 7b) were reduced in PLX5622-treated compared
with control-treated mice (Fig. 7i, j). While no differences in the overall number of cells expressing MHCII
were observed in P2RY12+CD45+, a significant reduction
of MHCII+CD11b+P2RY12negCD45+ was seen (Fig. 7c, d,
l). This corresponded with a relative increase in the percentage of MHCII+ cells in both P2RY12+CD45+ and
CD11b+P2RY12negCD45+ populations due to the decreased numbers of total P2RY12+CD45+ and
CD11b+P2RY12negCD45+ cells in the cortices of
PLX5622-treated mice compared with control-treated
mice (Fig. 7k). However, the numbers of P2RY12+CD45+
cells expressing B7 co-stimulatory signals CD80 and
CD86 were significantly reduced in the CNS of
PLX5622-treated mice compared with control-treated
animals (Fig. 7e–h, m–p). The percentage of remaining
P2RY12+CD45+ cells expressing CD80 or CD86 were
not reduced (Fig. 7m, o); however, the percentage of
remaining CD11b+P2RY12negCD45+ cells expressing
CD86 was significantly reduced (Fig. 7o), similar to results seen in peripheral APCs (Figs. 4, 5) Together, these
data suggest that resident microglia and infiltrating macrophages are important sources of CD80 and CD86 in
the CNS, and PLX5622 treatment depletes these cellular
sources of co-stimulatory molecules.

Discussion
Recent studies have reported increased viral titers in the
CNS of mice treated with CSF1R antagonists [36, 60, 61];
however, the mechanisms underlying this loss of virologic
control and the effects on peripheral immune responses
have not been well characterized. We sought to determine
the role of CSF1R signaling in viral clearance of both systemic and neurotropic infection. Our results indicate that
antagonism of CSF1R signaling limits virologic control
within the CNS via reduction of critical APCs that express
co-stimulatory B7 molecules, CD80 and CD86, necessary
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Fig. 5 CSF1R antagonism reduces co-stimulatory signal 2 on splenic APCs during i.c. infection with WNV-NS5-E218A. Mice were fed PLX5622 chow or
control chow for 2 weeks, then infected i.c. with WNV-NS5-E218A (104 PFU). At 8 dpi, splenic leukocytes were analyzed. a Representative flow
cytometry contour plots of CD11c and MHCII expression on CD45+-gated cells and b quantification of percentages and c total numbers of
CD11c+MHCII+CD45+ cells. d Representative flow cytometry plots of CD80 expression on CD11c+MHCII+CD45+ cells. e Quantification of percentages
and f total numbers of CD80+CD11c+MHCII+CD45+ cells. g Representative flow cytometry plots of CD86 expression on CD11c+MHCII+CD45+ cells.
h Quantification of percentages and i total numbers of CD86+CD11c+MHCII+CD45+ cells. j Representative flow cytometry histograms of CD80
expression on CD11c+MHCII+CD45+ and k quantification of MFI. l Representative flow cytometry histograms of CD86 expression on
CD11c+MHCII+CD45+ and m quantification of MFI. AU, arbitrary units. For quantification panels, each symbol represents an individual control- (black)
or PLX5622-treated (red) mouse, and bars indicate mean ± SEM. Data represent analysis from one experiment with three to four mice per group.
Statistical significance was calculated using unpaired two-way t tests. For all data: ns, not significant at P < 0.05; *P < 0.05; **P < 0.01

for local reactivation of antiviral CD8+ T cells. Our data
also indicate that CSF1R antagonism reduces expression
of co-stimulatory B7 molecules on peripheral APCs, contributing to loss of virologic control in the periphery and
dissemination of virus to the CNS. As previously reported,
WNV-NY inoculated into mice via f.p. is detected first

within the olfactory bulb then spreads caudally through
the cerebral cortex to the brain stem with significant virus
not detected in the cerebellum until 8 dpi [20]. CSF1R antagonism with PLX5622 leads to increased viral replication within each of these CNS regions and also in the
peripheral organs: the spleen, kidney, and serum. In
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Fig. 6 CSF1R antagonism does not hinder antiviral T cell recruitment to the CNS, but recruited T cells lack full activation during i.c. infection with
WNV-NS5-E218A. Mice were fed PLX5622 chow or control chow for 2 weeks, then infected i.c. with WNV-NS5-E218A (104 PFU). At 8 dpi,
leukocytes were isolated from the cortex and analyzed by flow cytometry. a Representative flow cytometry plots of CD45+-gated cells analyzed
by CD11b vs CD45 expression, identifying three populations of cells: CD11b+CD45lo (P1), CD11b+CD45hi (P2), and CD11bnegCD45hi (P3).
b Quantification of percentages and c number of cells in each gate. d Representative flow cytometry plots of CD4 vs CD8 expression and
e quantification of percentages and f total numbers of CD4+ vs CD8+ cells within P3 gate. g Representative flow cytometry plots of NS4B+
WNV-specific tetramer staining and h quantification of percentages and i total number of NS4B+CD8+CD45+ cells. j Representative flow cytometry
plots of CD69 expression on NS4B+CD8+CD45+ cells and k quantification of percentages, l total numbers, and m MFI of CD69+NS4B+CD8+CD45+
cells. n Representative flow cytometry plots of CD160 expression on NS4B+CD8+CD45+ cells and o quantification of percentages, p total numbers,
and q MFI of CD160+NS4B+CD8+CD45+ cells. MFI quantifications are shown as arbitrary units (AU) by normalizing each sample to the MFI of FMO
negative control value [77]. For quantification panels, each symbol represents an individual control- (black) or PLX5622-treated (red) mouse, and
bars indicate mean ± SEM. Data presented are the compilation of two independent experiments with seven to nine mice per group. Statistical
significance was calculated using unpaired t tests with Welch’s correction. For all data: ns, not significant at P < 0.05; *P < 0.05; **P < 0.01;
***P < 0.001; ****P < 0.0001
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Fig. 7 Microglia supply co-stimulatory signal 2 for T cell activation in the WNV-NS5-E218A-infected CNS. Mice were fed PLX5622 chow or control
chow for 2 weeks, then i.c. infected with WNV-NS5-E218A (104 PFU). At 8 dpi, leukocytes were analyzed from the cortex. a Representative flow
cytometry contour plots of P2RY12 expression on CD45+-gated cells to identify resident microglia (P1). b Representative flow cytometry plots of
CD11b expression on P2RY12negCD45+ cells to identify infiltrating macrophages (P2). c, d Representative flow cytometry plots of MHCII expression
on c P1 microglia and d P2 macrophages. e, f Representative flow cytometry plots of CD80 expression on e P1 microglia and f P2 macrophages.
g, h Representative flow cytometry dot plots of CD86 expression on g P1 microglia and h P2 macrophages. i, j Quantification of flow cytometry
analysis of i percentages and j total numbers of P1- vs P2-gated cells. k Quantification of percentages and l total numbers of MHCII+CD45+ cells
within each P1 and P2 population. m Quantification of percentages and n total number of CD80+CD45+ cells within each P1 and P2 population.
o Quantification of percentages and p total numbers of CD86+CD45+ cells within each P1 and P2 population. For quantification panels, each
symbol represents an individual control- (black) or PLX5622-treated (red) mouse, and bars indicate mean ± SEM. Data presented are the
compilation of two independent experiments with seven to nine mice per group. Statistical significance was calculated using multiple t tests with
Welch’s correction. For all data: ns, not significant at P < 0.05; *P < 0.05; **P < 0.01; ***P < 0.001; ****P < 0.0001

contrast to CNS titers, the virus is cleared from the spleen
and serum by 8 dpi in WNV-infected, control, and
PLX5622-treated mice. Notably, we detected expansion of
viral tropism with significant viral replication in the kidney
of PLX5622-treated mice at 4 and 6 dpi compared with
control-treated animals. These data suggest that renal
macrophages may be sensitive to CSF1R antagonism,
which is consistent with a study utilizing a model of recovery from acute kidney injury in which CSF1R inhibition with GW2580 reportedly decreased both kidney
macrophage proliferation and their polarization towards
wound-healing phenotypes [62]. In order to better isolate
the role of microglia during neurotropic infection, we examined the effect of PLX5622 in an established murine
model of CNS infection using an attenuated strain of
WNV (WNV-NS5-E218A), which lacks 2′-O-methyltransferase activity, thus increasing sensitivity to
IFIT-mediated suppression and limiting virulence in peripheral organs with intact immunity [8, 45, 49]. Mice infected i.c. with WNV-NS5-E218A exhibited increased
viral titers in the CNS and increased lethality with
PLX5622 treatment compared with control treatment.
These data suggest that loss of CNS immunity increases
lethality of WNV infection.
Clearance of WNV within the CNS requires local reactivation of antiviral CD8+ T cells for efficient T
cell-mediated adaptive immune responses [55, 63].
Under homeostatic conditions, microglia express very
low levels of co-stimulatory B7 molecules (CD80/CD86);
however, microglia upregulate expression of these molecules in response to inflammatory cytokines [54, 64].
Our results show PLX5622 treatment decreased expression of these molecules by depleting their cellular
sources in the CNS, which include both resident microglia and infiltrating monocytes/macrophages. In the periphery, PLX5622 also reduced cellular expression of B7
molecules on splenic, blood, and pLN APCs. Under certain conditions, other co-stimulatory molecules are able
to compensate for the loss of B7 signals in T cell reactivation. For example, expansion of lymphocytic choriomeningitis virus-specific antiviral T cells can be driven

by either alternative co-stimulatory TNFR superfamily
members or by enhanced expression of antiviral cytokines, such as high levels of type I IFNs [65]. However,
during WNV encephalitis, PLX5622 treatment also significantly decreased transcriptional expression of both
TNF and IFNβ. Together, our results indicate that
CSF1R antagonism contributes impaired local reactivation of antiviral T cells within the CNS by depleting
co-stimulatory signals including both B7 molecules and
inflammatory cytokines.
In addition to augmenting antiviral T cell activation,
many cytokines have essential protective roles during
WNV infection. Infected human monocyte-derived macrophages release IL-8, IFNα, IFNβ, and TNF [66, 67].
Microglia become activated in response to neurotropic
WNV infection and upregulate expression of CXCL10,
CXCL1, CCL5, CCL3, CCL2, TNF, and IL-6 [18]. Neurons and astrocytes in WNV-infected brains also release
proinflammatory mediators including CCL2, CCL5,
CXCL10, IL1β, IL-6, IL-8, and TNF, which promote
lymphocyte trafficking to the CNS [19–21]. In fact,
results from a recent study demonstrated that peripheral infection with WNV increased CNS expression of
chemokines important for lymphocyte trafficking, including CCL2, CCL7, CXCL9, and CXCL10, in
PLX5622-treated mice compared with control-treated
mice [61]. Type I IFN response is widely accepted as
the most immediate antiviral host response, essential
for controlling viral replication during the initial infection. Mice lacking type I IFN signaling are highly
vulnerable to uncontrolled WNV replication, exhibiting 100% mortality [68]. Clearance of viral infections,
however, requires additional immune response including type II IFN, i.e., IFNγ, which is produced by activated CD8+ T cells. Mice deficient in IFNγ show
higher peripheral viral load, increased CNS infection,
and increased lethality [69]. Data described here show
significantly decreased cytokine expression in
PLX5622-treated mice, which may also contribute to
the loss of virologic control via the above-described
mechanisms.
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The exact role of microglia during viral infection has
been difficult to define because infiltrating monocytes
can mask the impact of resident microglia. In a previous
report, IL34−/− mice, which have significantly reduced
development of microglia, are more susceptible to lethal
infection after WNV-NS5-E218A i.c. inoculation [36].
Similar to results reported here, IL34−/− mice exhibited
increased neuronal death compared with wildtype controls. In contrast with PLX5622-treated mice, IL34−/−
mice exhibited similar levels of viral burden compared
with wildtype controls in the brain at 3 and 6 dpi. Numbers of infiltrating monocytes/macrophages and
WNV-specific T cells were also similar between IL34−/−
and wildtype controls; however, the authors did not investigate antiviral T cell activation in this model [36]. In
another model of flavivirus encephalitis, in which suckling mice were infected with dengue virus, depletion of
microglia with liposome-encapsulated clodronate resulted in increased viral replication and reduced infiltration of IFNγ+CD8+ T cells [70]. Here, we report no
reduction in CD8+ T cell infiltration; however, this difference may be due to the age of mice, virus, and/or
method of microglial depletion. Another recent study reported use of PLX5622 in a model of neuroattenuated
murine corona virus, mouse hepatitis virus (MHV).
Similar to our results, PLX5622 treatment resulted in increased viral replication and lethality. In contrast to our
results, PLX5622 treatment reduced expression of
MHCII on microglia and macrophages and reduced
CD4+ T cell response [60]. While CD4+ T cells can improve CD8+ T cell response, the dependence of CD8+ T
cells on CD4+ T cells varies by virus, antigen exposure,
tissue environment, and effector sites [71]. In models of
MHV encephalitis, control of viral replication requires a
collaborative effort between CD4+ and CD8+ T cells
[71]. However, when virus replication induces activation
of APCs, activation of CD8+ T cells is relatively CD4+ T
cell-independent [71].
Recently, chronic activation of innate immune response by microglia is believed to be a major contributor
to neurodegenerative conditions [72]. Genetic studies
have confirmed the relevance of inflammatory response
in common neurodegenerative diseases, such as Alzheimer’s disease and multiple sclerosis, indicating that neuroinflammation is likely implicated in the primary
pathogenesis, rather than a secondary response [73]. We
and others have reported that microglia impact neurocognitive function by executing complement-mediated
synapse elimination [8, 74, 75]. Because of the neurological consequences of microglial activation, researchers
have attempted to use CSF1R antagonism to deplete
microglia in a variety of models to improve neurological
function, including traumatic brain injury [38, 39],
brain irradiation [50], myelin-induced catatonia [76],
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experimental autoimmune encephalomyelitis [40], and
Alzheimer’s disease [41]. However, our results indicate
that CSF1R antagonism may ultimately be detrimental
to brain health due to loss of innate and adaptive immune response in the CNS, as well as decreased peripheral APC activation. Thus, in assessing the benefit
of CSF1R antagonism, it will be important to consider
the diminished immune response in both the CNS
and peripheral immune compartments.

Conclusions
This study provides evidence that CSF1R signaling is critically important for cellular immunity during WNV
neurotropic infection. Pharmacologic antagonism of
CSF1R signaling limits expression of co-stimulatory signals through depletion of CNS cellular sources and decreased expression on peripheral APCS. This reduces
local restimulation of antiviral CD8+ T cells within the
CNS and results in loss of virologic control and increased
mortality. These data raise important considerations regarding the use of CSF1R antagonists for the treatment of
neurological disorders associated with neuroinflammation.
Additional files
Additional file 1: Example gating strategies and P2RY12 staining
specificity. Mice were fed chow containing PLX5622 or control chow for
2 weeks, then P2RY12 microglia staining was assessed by flow cytometry
in the (A–C) forebrain, (D–F) hindbrain, (G–I) blood, (J–L) spleen, and
(M–O) bone marrow of uninfected mice. (A, D, G, J, M) Representative
flow cytometry dot plots are shown for each tissue type to demonstrate
gating strategy to identify CD45+ cells. (B, C, E, F, H, I, K, L, N, O)
Representative flow cytometry dot plots of P2RY12 expression on CD45+ cells
in (B, E, H, K, N) control- and (C, F, I, L, O) PLX5622-treated mice in each tissue.
(P) Quantification of percentages and (Q) numbers of P2RY12+CD45+ cells in
the forebrain (FB), hindbrain (HB), blood (Bl), spleen (Sp), and bone marrow
(BM). For quantification panels, each symbol represents an individual control
(black) or PLX5622 (red)-treated mouse, and bars indicate mean ± SEM. Data
shown represent analysis from one experiment with 5 mice per group,
repeated in two independent experiments. Statistical significance was
calculated using two-way ANOVA with Sidak’s multiple comparisons test.
*P < 0.05; **P < 0.01; ****P < 0.0001. (TIF 14813 kb)
Additional file 2: PLX5622 broadly depletes Iba1+ cells. Mice were fed
chow containing PLX5622 or control chow for 2 weeks, then microglia
depletion was assessed by Iba1 immunohistochemical staining in the (A)
hippocampus, (B) cortex, and (C) cerebellum. (D) Quantification of
confocal microscopic images for number of Iba1-positive DAPI-positive
cells per high-power field (HPF) in the hippocampus (Hpc), cortex (Ctx), and
cerebellum (Cb). Three to six images were captured at × 40 per brain region
across two separate brain sections for each of four to five independent mice
collected in one experiment. Each symbol represents the average number
for an individual mouse, with bars indicating mean ± SEM. Statistical
significance was calculated using two-way ANOVA with Sidak’s multiple
comparisons test, P < 0.05; *P < 0.05; **P < 0.01. (TIF 11593 kb)
Additional file 3: PLX5622 treatment does not impact T cell
populations in peripheral immune compartments of uninfected mice.
Mice were fed PLX5622 or control chow for 2 weeks, then T cell
populations were assessed in (A, B, E, F) blood and (C, D, G, H) spleen of
uninfected mice. (A, C) Representative flow cytometry plots and example
gating strategy to identify CD45+ cells. (B, D) Representative flow
cytometry plots of CD4 vs CD8 expression on CD45+ cells. (E, G)
Quantification of percentages and (F, H) total numbers of CD4+CD45+ vs
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CD8+CD45+ cells in uninfected mice. For quantification panels, each
symbol represents an individual control (black) or PLX5622 (red)-treated
mouse, and bars indicate mean ± SEM. Data shown represent analysis
from one experiment with three to five mice per group, repeated in
three independent experiments. Multiple unpaired t test analyses indicate
no significant difference among any of these populations. (TIF 8042 kb)
Additional file 4: PLX5622 treatment does not impact macrophage/
monocyte population in peripheral immune compartments of uninfected
mice. Mice were fed PLX5622 chow or control chow for 2 weeks, then
monocytes/macrophages were assessed in (A–F) blood, (G–L) spleen, and
(M–R) bone marrow of uninfected mice. (A, G, M) Representative flow
cytometry plots of CD11b expression on CD45+-gated cells. (B, H, N)
Quantification of percentages and (C, I, O) total numbers of
CD11b+CD45+ cells. (D, J, P) Representative flow cytometry plots of Ly6G
vs Ly6C expression on CD11b+CD45+ cells. (E, K, Q) Quantification of
percentages and (F, L, R) total numbers of Ly6G+CD45+ vs Ly6C+CD45+
cells. For quantification panels, each symbol represents an individual
control (black) or PLX5622 (red)-treated mouse, and bars indicate mean
± SEM. Data shown represent analysis from one experiment with five
mice per group, repeated in three independent experiments. Multiple
unpaired t test analyses indicate no significant difference among any of
these populations. (TIF 11595 kb)
Additional file 5: PLX5622 treatment does not enhance BBB
permeability. Mice were fed PLX5622 chow or control chow for 2 weeks,
then infected via footpad with WNV-NY (102 PFU). BBB permeability was
measured by detection of sodium fluorescein accumulation in brain
tissue homogenates derived from (A) olfactory bulb, (B) cortex, (C)
cerebellum, (D) brainstem, and (E) spinal cord. Data are represented
as mean ± SEM of individual mouse values normalized to serum
sodium fluorescein concentration. Group means were then
normalized to the mean values for uninfected controls. Statistical
significance was calculated using two-way ANOVA with Sidak’s multiple
comparisons test, indicating significantly different curves, but no significant
difference at any 1 day. *P < 0.05; **P < 0.01; (TIF 3314 kb)
Additional file 6: Control and PLX5622-treated CNS tissue are equally
permissive to WNV-NY infection. Mice were fed chow containing PLX5622
or control chow for 2 weeks, infected i.c. with 10 PFU WNV-NY, and then
monitored for (A) mortality and (B) weight loss. (A) Mice universally die from
i.c. infection with WNV-NY regardless of PLX5622 treatment, with no
difference in length of survival as calculated by log-rank (Mantel-Cox) test.
(B) Weight was measured daily during acute illness as a measure of illness.
After death, the last measured weight was carried through to the end of
the experiment. Statistically significant greater weight loss was measured in
control mice compared with PLX5622-treated mice as calculated by
two-way ANOVA with matched values comparing group means without
multiple comparisons. (C-I) Tissue viral loads were measured by plaque assay
at 2 and 4 dpi in control (black) or PLX5622-treated (red) mice. (J) Serum
viral loads as measured by qRT-PCR. For viral titers, each symbol represents an
individual control (black) or PLX5622 (red)-treated mouse and bars indicate
mean. Dotted line indicates assay limit of detection. Data shown represent
analysis from one experiment with five mice per group. Statistical significance
was calculated using two-way ANOVA with Sidak’s multiple comparisons test.
ns, not significant at P < 0.05; *P < 0.05; ****P < 0.0001. (TIF 7958 kb)
Additional file 7: Impact of CSF1R antagonism on APC co-stimulatory
expression is tissue-dependent. Mice were fed PLX5622 or control chow
for 2 weeks, then infected via f.p. with WNV-NY (100 PFU). At 4 dpi,
leukocytes were isolated from blood (A–C) and draining popliteal LNs
(D–F). (A) Representative flow cytometry plots of CD86 expression on
CD11c+CD45+-gated cells in the blood. (B) Quantification of percentages
and (C) total numbers of CD86+CD11c+CD45+ cells in the blood. (D)
Representative flow cytometry plots of CD80 expression on
CD11c+CD45+-gated cells in the pLN. (E) Quantification of percentages
and (F) total numbers of CD80+CD11c+CD45+ cells in the blood. For
quantification panels, each symbol represents an individual control (black)
or PLX5622 (red)-treated mouse, and bars indicate mean ± SEM. Data
shown represent analysis from one experiment with four to five mice per
group. Statistical significance was calculated using unpaired t test. For all
data: ns, not significant at P < 0.05; *P < 0.05; **P < 0.01. (TIF 4465 kb)
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Additional file 8: PLX5622 treatment does not impact T cell activation
in spleens of WNV-NS5-E218A infected mice. Mice were fed PLX5622 or
control chow for 2 weeks, then infected i.c. with WNV-NS5-E218A
(104 PFU). At 8 dpi, splenic leukocytes were isolated and analyzed by flow
cytometric analysis. (A) Representative flow cytometry gating strategy for
CD45+ cells. (B) Representative flow cytometry contour plots of CD4 vs
CD8 expression on CD45+-gated cells. (C) Quantification of percentages
and (D) total numbers of CD4+CD45+ vs CD8+CD45+ cells. (E) Representative
flow cytometry plots of WNV-specific NS4B+ tetramer staining of
CD8+CD45+ cells. (F) Quantification of percentages and (G) total numbers of
NS4B+CD8+CD45+ cells. (H) Representative flow cytometry plots of CD69
expression on NS4B+CD8+CD45+ cells. (I) Quantification of percentages and
(G) total numbers of CD69+NS4B+CD8+CD45+ cells. For quantification
panels, each symbol represents an individual control (black) or PLX5622
(red)-treated mouse, and bars indicate mean ± SEM. Data shown represent
analysis from one experiment with three to five mice per group. Multiple
unpaired t test analyses indicate no significant difference among any of
these populations. (TIF 7349 kb)
Abbreviations
APC: Antigen-presenting cell; BBB: Blood brain barrier; CNS: Central nervous
system; CSF1R: CSF1 receptor; DPI: Days post-infection; FMO: Fluorescence
minus one; PFA: Paraformaldehyde; qRT-PCR: Quantitative RT-PCR; WNV: West
Nile virus
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